About Arontier
Arontier is a company based in Seoul (South Korea) founded in 2017 by Insuk Sohn. Arontier offers products and services including Antibody Design, Protein/Peptide Binder Design, and Small-Molecule Drug Design. Arontier operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seoul, South Korea
- Founders Insuk Sohn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Arontier
Arontier offers a comprehensive portfolio of products and services, including Antibody Design, Protein/Peptide Binder Design, and Small-Molecule Drug Design.
AI tool for designing antibody therapeutics based on data-driven methods.
Generative AI for creating functional protein binders in drug development.
AI-assisted exploration for selective small-molecule drug candidates.
Funding Insights of Arontier
Detailed funding history for Arontier
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arontier
Investment portfolio details for Arontier
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arontier
Detailed financials for Arontier
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arontier Comparisons
Peer comparison for Arontier
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arontier
Arontier operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Arontier
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arontier
Complete news archive for Arontier
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arontier
Arontier was founded in 2017.
Arontier is headquartered in Seoul, South Korea.
Arontier was founded in 2017 in Seoul, South Korea, within the biotechnology sector. An AI-powered platform is employed for drug discovery targeting cancer and rare diseases. Bioinformatic analysis, drug genomics, and screening technologies are integrated to develop anti-CAF drugs. These drugs are designed to disrupt interactions that render cancer cells resistant to therapies, thereby enhancing treatment vulnerability. Operations are centered on advancing therapeutic interventions through computational and experimental methods.
Arontier's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Arontier offers Antibody Design, Protein/Peptide Binder Design, and Small-Molecule Drug Design.